secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001367644-23-000004
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions preliminary 2022 rev down 38%, adj net loss $70-90M, cuts 5% workforce, exec departures
--------------------------------------------------------------------------------

- Preliminary 2022 revenue $1.1-1.12B, down 38% YoY; adj net loss $70-90M; adj EBITDA $20-40M.
- Restructuring eliminates 132 roles (5% workforce) with $9-11M charges in Q1 2023; annual savings >$60M.
- EVP Katy Strei (CPO) and EVP Atul Saran (CSDO) to depart March 17; Michelle Pepin promoted to CHRO.
- Paul Williams appointed SVP Products Business leading MCM and NARCAN; Kelly Warfield leads new S&D function.
- 2023 financial outlook deferred to late February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/0001367644-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000004/ebs-20230109.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer